Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2005

01-02-2005 | Original Article

Polymorphism of interleukin-10 promoter and tumor necrosis factor receptor II in Vietnamese patients with systemic lupus erythematosus

Authors: Pham Dang Khoa, Tsuyoshi Sugiyama, Takashi Yokochi

Published in: Clinical Rheumatology | Issue 1/2005

Login to get access

Abstract

The polymorphism of the interleukin-10 (IL-10) promoter and tumor necrosis factor receptor II (TNFRII) in Vietnamese patients with systemic lupus erythematosus (SLE) was examined by using the polymerase chain reaction (PCR) method with genomic DNA and allele-specific primers. In the frequency of IL-10 promoter 1082 genotypes consisting of AA, A/G and GG, the allele frequency of G in the SLE patients was significantly higher than that in the healthy controls. On the other hand, there was no statistical difference in the frequency of TNF receptor (TNFR) II 196 genotypes between the SLE patients and healthy controls. It was therefore suggested that the polymorphism of the IL-10 promoter, but not TNFRII, might participate in the pathogenesis of SLE in Vietnamese.
Literature
1.
2.
Maini RN, Elliott MJ, Charles PJ, Feldmann M (1994) Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunopathol 16:327–336PubMed
3.
Hagiwara E, Gouley MF, Lee S, Klinman DK (1996) Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 39:397–385CrossRef
4.
Eskdale J, Kube D, Gallagher G (1996) A second dinucleotide repeat in the 5’ flanking region of the human IL10 gene. Immunogenetics 45:82–83PubMedCrossRef
5.
Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RGJ, Huizinga TWJ (1998) Interleukin-10 secretion in relation to human IL-10 locus haplotype. Proc Natl Acad Sci U S A 95:9465–9470PubMedCentralPubMedCrossRef
6.
Kube D, Platzer C, von Knethen A, Straub H, Bohlen H, Hafner M, Tesch H (1995) Isolation of the human IL10 promoter: characterization of the promoter activity in Burkitt’s lymphoma cell lines. Cytokine 7:1–7PubMedCrossRef
7.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin 10 gene promoter. Eur J Immunogenet 41:1090–1095
8.
Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 87:1233–1237PubMedCentralPubMedCrossRef
9.
Beltinger CP, White PS, Maris JM (1996) Physical mapping and genomic structure of the human TNFR2 gene. Genomics 35:94–100PubMedCrossRef
10.
Kollias G, Douni E, Kassiotis G, Kontoyannis D (1999) The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58:132–139CrossRef
11.
Lin RH, Hwang YW, Yang BC, Lin CS (1997) TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD 28 costimulation. J Immunol 158:598–603PubMed
12.
Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24:303–308PubMed
13.
Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K (1999) Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 53:527–533PubMedCrossRef
14.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
15.
16.
Perrey C, Turner ST, Pravica V, Howell WM, Hutchinson IV (1999) ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 7:127–128PubMedCrossRef
17.
Al-Ansari AS, Ollier WE, Villarreal J, Ordi J, Teh LS, Hajeer AH (2000) Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 55:97–99PubMedCrossRef
18.
D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richiardi P (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43:120–128CrossRef
19.
Gibson AW, Edberg JC, Wu J, Westendorp RGJ, Huizinga TWJ, Kimberly RP (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915–3922PubMedCrossRef
20.
Ou TT, Tsai WC, Chen CJ, Chang JG, Yen JH, Wang WS, Lin CH, Tsai JJ, Liu HW (1998) Genetic analysis of interleukin-10 promoter region in patients with systemic lupus erythematosus in Taiwan. Kao Hsiung J Med Sci 14:599–606
21.
Mok CC, Lanchbury JS, Chan DW, Lau CS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41:1090–1095PubMedCrossRef
22.
Alarcon-Riquelme ME, Lindqvist AKB, Jonasson I, Johanneson B, Sandino S, Alcocer-Varela J, Granados J, Kristjansdottir H, Grondai G, Svenungsson E, Lundberg I, Steinsson K, Klareskog L, Sturfelt G, Truedsson L, Alarcon-Segovia D, Gyllensten UB (1999) Genetic analysis of the contribution of IL10 to systemic lupus erythematosus. J Rheumatol 26:2148–2152PubMed
23.
Lee EB, Yoo JE, Lee YJ, Choi YJ, Park KS, Song YW (2001) Tumor necrosis factor receptor 2 polymorphism in systemic lupus erythematosus: no association with disease. Hum Immunol 62:1148–1152PubMedCrossRef
Metadata
Title
Polymorphism of interleukin-10 promoter and tumor necrosis factor receptor II in Vietnamese patients with systemic lupus erythematosus
Authors
Pham Dang Khoa
Tsuyoshi Sugiyama
Takashi Yokochi
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0952-1

Other articles of this Issue 1/2005

Clinical Rheumatology 1/2005 Go to the issue

Case Report

p-ANCA-associated periaortitis with histological proof of Wegener’s granulomatosis: case report

Case Report

Successful neridronate therapy in transient osteoporosis of the hip

Original Article

Health-related quality of life in patients with hip or knee osteoarthritis: comparison of generic and disease-specific instruments

Original Article

Relationship between high-resolution computed tomography findings and the Stoke index in patients with rheumatoid arthritis

Case Report

Transverse myelitis in a patient with Behcet’s disease: favorable outcome with a combination of interferon-α

Original Article

Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits